Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information
- PMID: 12210341
- DOI: 10.1002/ajmg.10550
Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information
Abstract
Genetic counseling for individuals at high risk for developing breast and ovarian cancer (oncogenetic counseling) involves evaluation of cancer risk, psychological assessment, and genetic testing for germline mutations in BRCA1/BRCA2 genes. The long-term psychosocial impact of oncogenetic counseling on consultees and the retention of oncogenetic information are uncertain. We retrospectively interviewed 155 women who underwent oncogenetic counseling in a single medical center in Israel in 1996 (N = 50) and 1998 (N = 105). There were 29 (18.7%) BRCA1/BRCA2 mutation carriers and 126 non-carriers; 58 (37.4%) had a past or present history of cancer, and 97 (62.6%) were first-degree relatives within breast/ovarian cancer families. A questionnaire evaluating self-reported distress and anxiety symptoms before and after counseling, as well as the retention of relevant information (e.g., individual and offspring cancer risk, early detection schemes), one and three years after the initial consultation was administered. Overall, oncogenetic counseling had a minimal effect on anxiety-related symptoms. Mutation carriers reported anxiety-associated symptoms, such as sleeplessness and "bad mood", more frequently than non-carriers following oncogenetic counseling. As expected, 61.8% of carriers and only 30% of non-carriers accurately remembered the personal and offspring cancer risk and preventive and early detection schemes. We conclude that although there seemed to be slight worsening of anxiety-related symptoms following oncogenetic counseling in BRCA1/BRCA2 mutation carriers, these symptoms were minimal and did not affect everyday life activities. In addition, there is an ongoing need to emphasize oncogenetic information to high-risk individuals.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.Eur J Hum Genet. 2001 Jul;9(7):492-500. doi: 10.1038/sj.ejhg.5200668. Eur J Hum Genet. 2001. PMID: 11464240
-
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589
-
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11535547
-
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.Eur J Cancer Prev. 2000 Jun;9(3):139-50. Eur J Cancer Prev. 2000. PMID: 10954253 Review.
-
[Tumor risk consultation for predisposed women from high risk cancer families].Praxis (Bern 1994). 1998 Apr 8;87(15):511-5. Praxis (Bern 1994). 1998. PMID: 9608246 Review. German.
Cited by
-
Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.Fam Cancer. 2005;4(2):121-6. doi: 10.1007/s10689-004-7995-y. Fam Cancer. 2005. PMID: 15951962
-
Distress and family functioning in oncogenetic counselling for hereditary and familial breast and/or ovarian cancers.J Genet Couns. 2007 Oct;16(5):625-34. doi: 10.1007/s10897-007-9102-7. Epub 2007 Aug 15. J Genet Couns. 2007. PMID: 17701329
-
BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer.Hered Cancer Clin Pract. 2019 Feb 27;17:7. doi: 10.1186/s13053-019-0107-7. eCollection 2019. Hered Cancer Clin Pract. 2019. PMID: 30858899 Free PMC article.
-
Supervision of psychosocial skills in genetic counseling.J Genet Couns. 2006 Aug;15(4):211-23. doi: 10.1007/s10897-006-9024-9. J Genet Couns. 2006. PMID: 16865562
-
Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up.Fam Cancer. 2004;3(2):109-16. doi: 10.1023/B:FAME.0000039863.89137.f9. Fam Cancer. 2004. PMID: 15340261
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous